Spouse Holding and a Live QIP Mandate
You cover mid-cap specialty chemicals. Your spouse owns INR 1.8 million of the company in a demat account. Your firm's investment banking arm has a live mandate for the company's INR 12 billion qualified institutional placement. The company's CFO is your cousin, and you speak to him weekly. Your model produces a target price 28% above the current market price, and you propose a Buy rating. The report is due tomorrow. The sales team wants a 'clean' note without a long disclosure section because clients find it distracting. Compliance has asked you to complete a conflict-of-interest checklist and to confirm whether you or your associates have traded the stock in the past 30 days. You bought INR 150,000 of the stock 20 days ago and have not sold.
1. Identify the conflicts in this situation and the disclosures that would be required.
Read the worked answer
There are at least four conflicts:
- Personal/family holding - your spouse's INR 1.8 million holding gives you and your household a financial interest in a rising price.
- Investment banking relationship - the firm earns fees from the QIP and has an incentive for a favourable rating.
- Personal relationship with the CFO - weekly contact with a close family member who is a senior insider can compromise objectivity and may create access to non-public information.
- Your own recent purchase - the INR 150,000 purchase 20 days before a planned publication creates a personal trading conflict.
Disclosures should cover the spouse's holding, your own holding, the investment banking mandate and compensation, the CFO relationship, and the fact that the firm may seek the QIP mandate. The disclosure must be specific and prominent, not buried in boilerplate. 'Clean note' pressure from sales is not a reason to shorten it; incomplete disclosure can itself mislead clients.
The relationship with the CFO should also be escalated to compliance. Even if a cousin is not a 'relative' under a narrow definition, the weekly contact and seniority of the CFO create a conflict that requires review and possibly a wall between your research and any non-public corporate information.
2. Can you publish the Buy rating tomorrow? What conditions would compliance need to impose?
Read the worked answer
Not as currently planned. Publishing tomorrow would mean you are issuing a positive recommendation while you bought the stock 20 days earlier, which falls inside the standard no-dealing window around publication. It would also put a Buy rating on a stock in which your spouse has a material holding and your firm is seeking a large QIP mandate.
The cleanest options are:
- Delay publication until the no-dealing window has cleared and compliance has approved the conflict disclosures; or
- Recuse yourself and hand coverage to an analyst with no holding, no CFO relationship, and no involvement in the QIP; or
- Do not publish a rating and instead issue a factual, non-recommendatory update if the firm's policies allow it.
If publication proceeds after clearance, conditions should include independent supervisory review of the target price and assumptions, prominent conflict disclosure, a restriction on your personal dealing, a wall between research and the QIP team, and a prohibition on the banking team reviewing the rating or target price before publication. Disclosure alone does not neutralise a conflict of this size; the firm must be able to show that the recommendation was independently reached.
3. What should you do about the purchase 20 days ago and the sales team's request for a short disclosure?
Read the worked answer
Report the purchase to compliance immediately, with the trade date, quantity, price, and account. Do not sell simply to 'fix' the conflict without advice, because a sale immediately before a positive report can itself look like trading on the report or on inside information. Compliance should decide whether the report is delayed, coverage is reassigned, or the holding is placed in a restricted account.
The sales team's request should be declined. The disclosure section exists to let clients judge the independence of the research. A short or vague disclosure ('the analyst may have interests') is worse than a specific one because it appears to hide the relationship. The analyst should document the sales request and the compliance response.
A practical approach is to prepare a disclosure matrix: each conflict, its nature, the person affected, the control applied, and the approval. If the firm cannot describe the control in one paragraph, it probably is not managing the conflict adequately.